Rare Diseases

Founded in 2018 by Professor Steve Jackson in partnership with Ahren Innovation Capital, Adrestia Therapeutics was a Cambridge-based biotech that pioneered a novel approach to treating intractable genetic diseases through what it called synthetic rescue. The company's Disease Rebalancing Platform mapped gene interaction networks across the human genome to identify molecular partners capable of restoring function in damaged, diseased, or dying cells, creating a systematic atlas of therapeutic opportunities that conventional target-selection methods could not reach. Therapy Areas and Pipeline Adrestia concentrated its early programmes on neurological, neuromuscular, and cardiomyopathic diseases. A notable collaboration with Dr Sarah Tabrizi at University College London focused on Huntington's disease, while a partnership with Proteros Biostructures in Munich accelerated the identification of first-in-class small-molecule candidates across multiple targets. The company also engaged Proteros to support structural biology and drug-discovery chemistry for its lead programmes. Partnerships and Acquisition GSK co-led Adrestia's Series A financing alongside Ahren Innovation Capital, establishing a multi-project discovery collaboration in which each of up to five joint programmes was eligible for up to $230 million in post-option development and commercialisation milestones, plus royalties. In August 2023, Insmed Incorporated (Nasdaq: INSM) acquired Adrestia, integrating its synthetic rescue technology into Insmed's early-stage rare disease research portfolio. Further information is available at adrestia.com.

Alcresta Therapeutics develops enzyme-based products targeting fat malabsorption in patients with rare diseases who rely on enteral feeding for nutrition. The company focuses on addressing a specific clinical gap: many patients requiring enteral nutrition cannot adequately digest fat, which is essential for growth, immune function, and organ health, with exocrine pancreatic insufficiency a recognised driver of this problem. Central to its pipeline is RELiZORB , a cartridge-based delivery system containing iLipase, a patented microbead and enzyme technology developed to improve fat digestion directly within the enteral feeding process. The product is designed for use both in hospital settings and by patients receiving enteral feeds at home, reflecting the real-world care environments where fat malabsorption creates the most significant clinical burden. Alcresta's development work spans pre-clinical and clinical study stages, with published real-world use studies contributing to the growing evidence base for its approach. The company's stated mission centres on enabling patients with serious medical conditions to absorb the nutritional benefits of enteral feeding, reducing the risk of poor outcomes associated with fat malabsorption. Based in the United States, Alcresta operates with a leadership structure that includes a board of directors, reflecting a governance model typical of a clinical-stage biotechnology firm. Its investor relations function and active careers programme indicate ongoing operations and continued development activity. Further information is available at alcresta.com.

Formed to bring the portfolio of its Italian parent directly to North American prescribers, Alfasigma USA is the dedicated US commercial subsidiary of Alfasigma S.p.A., the Bologna-headquartered pharmaceutical group created in 2016 through the merger of Alfa Wassermann and Sigma-Tau. The parent operates in more than 90 countries and employs over 3,000 people globally, with a broad product portfolio spanning gastroenterology , hepatology, metabolism and rare disease. US Commercial and Medical Affairs Operations Alfasigma USA manages the full commercial lifecycle for its prescription medicines in the United States, covering regulatory submissions to the FDA, medical affairs, pharmacovigilance and market access. The subsidiary works directly with physicians, gastroenterologists, specialist prescribers, pharmacists and payer organisations to support appropriate product access and patient support programmes. The gastroenterology and hepatology franchise is a core focus of the US operation, reflecting the parent group's longstanding research heritage in digestive health and liver function. Alfasigma USA operates within the frameworks established by the FDA and applicable federal healthcare regulations, functioning as an accountable commercial and regulatory presence rather than relying on third-party licensing or distribution arrangements. Further information is available at alfasigmausa.com.

The company that proved RNA interference could be turned into medicine, Alnylam Pharmaceuticals has built the world's leading RNAi therapeutics pipeline from the ground up. Founded in Cambridge, Massachusetts in 2002, the company was established with a singular mission: to harness the natural gene-silencing mechanism of RNA interference to treat diseases at their genetic root. What was once a Nobel Prize-winning biological discovery has, under Alnylam's stewardship, become a bona fide drug class. Approved Medicines and the GalNAc Platform Alnylam's commercial portfolio spans multiple approved products targeting serious, often rare, diseases. ONPATTRO (patisiran), approved in 2018, was the first-ever RNAi therapeutic to reach patients, indicated for hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis). It was followed by GIVLAARI (givosiran) for acute hepatic porphyria, OXLUMO (lumasiran) for primary hyperoxaluria type 1, and LEQVIO (inclisiran, developed with Novartis) for cardiovascular cholesterol management. Central to the commercial and pipeline strategy is the proprietary GalNAc conjugate delivery platform, which enables subcutaneous dosing and has significantly broadened the range of addressable targets in the liver. Pipeline Reach and Global Presence Beyond its approved medicines, Alnylam maintains an active investigational pipeline targeting conditions including transthyretin amyloidosis with cardiomyopathy, complement-mediated diseases, and hypertension, among others. The company operates globally, with offices and partnerships spanning North America, Europe, and Asia. Alnylam trades on the Nasdaq Stock Market under the ticker ALNY and is considered a large-cap biotechnology company. Its partnerships with major pharmaceutical companies, including a long-standing collaboration with Sanofi, have reinforced its commercial infrastructure and expanded patient access internationally. Alnylam's work represents a structural shift in how genetic medicine is approached, moving from managing symptoms to silencing the genes that cause disease in the first place. For medical affairs, licensing, and pipeline enquiries, further information is available at alnylam.com.

Founded in 1980 in Thousand Oaks, California, Amgen was one of the world's first biotechnology companies to industrialise the manufacture of proteins from living cells, a founding ambition that shaped modern biopharmaceuticals. Listed on Nasdaq under the ticker AMGN, Amgen has grown into one of the largest independent biotechnology companies globally, with operations spanning more than 100 countries and a workforce of tens of thousands. Core Therapy Areas and Pipeline Amgen's therapeutic focus covers oncology, haematology, cardiovascular disease, inflammation, bone health, and nephrology. The company's portfolio includes well-established products such as Enbrel for inflammatory conditions, Prolia and Xgeva for bone loss, and Repatha for cholesterol management. In oncology, its BiTE (bispecific T-cell engager) platform represents a distinctive approach to cancer immunotherapy , with Blincyto being one of the first approved BiTE molecules. The 2023 acquisition of Horizon Therapeutics expanded Amgen's rare disease capabilities, adding treatments for conditions such as thyroid eye disease and gout to its portfolio. Manufacturing and Global Infrastructure Amgen operates a substantial global manufacturing network, with large-scale biologics production facilities across the United States, Puerto Rico, Ireland, and Singapore. This internal manufacturing capability, built from the company's earliest years, gives Amgen end-to-end control over biologics production at commercial scale. The company has also invested in next-generation small molecule research alongside its biologics heritage, broadening its discovery toolkit. With decades of published research, long-standing academic and clinical partnerships, and a pipeline extending across multiple therapeutic categories, Amgen remains a central reference point for practitioners, researchers, and industry professionals working in the global pharmaceutical and biotechnology sector. Further information is available at amgen.com.

AMO Pharma is building a portfolio of new medicines targeting serious and debilitating diseases, with a particular focus on rare and orphan genetic disorders. The privately held emerging biopharmaceutical company , headquartered in London, identifies and advances promising therapies for patient populations facing significant unmet need, guided by the principle that clinical development should deliver measurable value to patients at every stage of the journey. The pipeline reflects that commitment. AMO Pharma is progressing multiple candidates, including AMO-01, AMO-02, and AMO-04, across conditions that include Phelan-McDermid Syndrome, Rett Syndrome, and congenital myotonic dystrophy . The REACH-CDM pivotal clinical trial for congenital myotonic dystrophy represents a significant milestone in the company's development programme. Each indication falls within the rare or orphan disease space, where AMO Pharma's strategy is to identify assets with high potential impact and advance them through all phases of development, from early research through to potential approval. The company is led by a team of seasoned industry professionals who bring extensive experience in biomedical science, research, and asset acquisition across all phases of pharmaceutical development. This experienced leadership team combines deep scientific knowledge with commercial expertise, enabling a disciplined approach to candidate selection and clinical execution. AMO Pharma also maintains an active partnerships function, reflecting a business model that combines internal expertise with external collaboration to move treatments forward for underserved patient communities. Further information is available at amo-pharma.com.

ANI Pharmaceuticals is a NASDAQ-listed integrated specialty pharmaceutical company (ticker: ANIP) focused on building a leading rare disease business. Operating across branded and generic prescription markets, the company develops, manufactures, and markets high-quality pharmaceuticals for patients with significant unmet needs. The company's rare disease focus is a defining strategic pillar, with FDA-approved products including Cortrophin serving as a flagship within its branded portfolio. ANI also operates a generics and other pharmaceuticals segment, broadening its commercial reach across multiple therapeutic categories. Manufacturing is a core competency. ANI offers contract manufacturing capabilities alongside its proprietary product lines, with quality systems and production facilities supporting both its own pipeline and third-party clients. Its operational footprint includes facilities in Baudette, Minnesota, and additional locations expanded through the acquisition of Novitium Pharma, which is now fully integrated into the ANI business. The company maintains a medical information portal for both its branded rare disease products and its generics range, reflecting a commitment to supporting healthcare professionals with accurate prescribing resources. ANI reported first quarter 2026 financial results in May 2026 and raised its full-year 2026 financial guidance, signalling continued commercial momentum. The company was also scheduled to present at the 2026 Jefferies Global Healthcare Conference in May 2026. Further information is available at anipharmaceuticals.com.

Europe's pioneer in integrated therapies for rare diseases and critical care, AOP Health (trading as AOP Orphan) brings together scientific rigour, clinical development and commercial delivery under one roof. The company operates at the intersection of rare disease medicine and intensive-care medicine, two areas where unmet patient need remains exceptionally high. The therapeutic focus spans cardiology and pulmonology, haemato-oncology, critical care, and advanced therapies. This breadth reflects a deliberate strategy to address conditions that are either underserved by mainstream pharmaceutical investment or require highly specialised clinical management. A patient story programme, including accounts of sepsis survival, illustrates the real-world impact the company seeks to communicate to partners, prescribers and policymakers alike. On the scientific side, AOP Health maintains an active clinical pipeline with new trials entering development, including a study of a novel treatment approach for blood cancers announced in June 2026. The company publishes its research findings and makes its innovation methodology available to industry audiences, reflecting an openness to scientific dialogue that is characteristic of organisations working in rare-disease areas subject to close regulatory scrutiny. AOP Health operates across multiple international locations and participates actively in the global congress calendar, including rare skin disease and haemato-oncology meetings. In June 2026, the company received a Gold award at the WKO Export Awards, recognising its performance as an Austrian exporter with international reach. This recognition underlines its standing as a commercially active, internationally operating pharmaceutical business, not merely a research-stage organisation. Further information is available at aop-health.com.

AstraZeneca is one of the world's largest biopharmaceutical companies , with its global headquarters at the Cambridge Biomedical Campus in England. Founded in 1999 through the merger of Astra AB of Sweden and Zeneca Group of the United Kingdom, the company is listed on the London Stock Exchange (AZN) and on Nasdaq, and employs approximately 90,000 people across more than 100 countries. Cambridge functions not merely as a corporate address but as the centre of the company's worldwide research and early development capability, hosting thousands of scientists working across discovery biology, chemistry, and translational medicine. Therapy Areas and Pipeline The company's research strategy concentrates on three main therapy area clusters: oncology, cardiovascular, renal and metabolic disease (CVRM), and respiratory and immunology (R&I). Within oncology, AstraZeneca markets established medicines including osimertinib (Tagrisso), olaparib (Lynparza, developed with MSD), and durvalumab (Imfinzi). The CVRM portfolio includes dapagliflozin (Farxiga/Forxiga), which has received regulatory approvals across heart failure, chronic kidney disease, and type 2 diabetes indications. The respiratory franchise covers budesonide/formoterol combinations and the biologic tezepelumab (Tezspire, developed with Amgen) for severe asthma. UK Operations and Clinical Development AstraZeneca UK operates across the full pharmaceutical value chain: early and late-stage clinical trials , regulatory affairs, medical affairs, market access, and commercial operations serving the National Health Service. The UK site at Cambridge is complemented by manufacturing and biologics development capabilities at sites including Macclesfield. The company collaborates extensively with the Medical Research Council, Cancer Research UK, and NHS England, and was a prominent partner in the University of Oxford COVID-19 vaccine programme, through which AstraZeneca's Vaxzevria was manufactured and distributed globally at no profit during the pandemic period. AstraZeneca participates in hundreds of sponsored clinical studies in the United Kingdom at any given time, engaging NHS trusts, academic medical centres, and independent research sites. The organisation also operates a patient access programme infrastructure and maintains a dedicated UK medical information service for healthcare professionals. Further information is available at astrazeneca.co.uk.

Boehringer Ingelheim ranks among the largest research-driven pharmaceutical companies in the world and, uniquely for a business of its scale, remains wholly family-owned, having operated independently since its founding in Ingelheim am Rhein, Germany, in 1885. That private ownership shapes everything from its long investment horizon to its willingness to pursue complex biology that publicly listed peers may avoid. Human and Animal Health The company operates across two distinct businesses. Its human pharma division concentrates on respiratory diseases , cardiovascular and metabolic conditions, oncology, and immunology, with established medicines spanning COPD, heart failure, type 2 diabetes, and idiopathic pulmonary fibrosis. The animal health division is one of the largest in the world, covering livestock and companion animal health across a broad portfolio of vaccines and therapeutics, a segment reinforced by the 2017 asset swap with Sanofi that brought in Merial. Global Research & Biopharmaceutical Manufacturing Boehringer Ingelheim maintains a significant contract manufacturing presence alongside its own pipeline work. Its biopharmaceutical contract manufacturing organisation arm, among the longest-established in the industry, produces biologics for third-party clients as well as internal programmes. Research centres span Germany, Austria, the United States, China, and other locations, with the company consistently investing a substantial proportion of net sales back into research and development each year. Its pipeline spans small molecules, biologics, and cell and gene therapy technologies, reflecting a deliberate push into next-generation modalities. The group employs tens of thousands of people across more than 130 markets globally. Headquartered in Ingelheim am Rhein, the company's independent status means it publishes net sales rather than stock-market results, with figures consistently placing it within the global top-ten pharmaceutical groups by revenue. Its therapy focus on diseases with significant unmet need, combined with a long-term ownership model, gives it a research culture oriented toward decade-spanning programmes rather than quarterly targets. Further information is available at boehringer-ingelheim.com.

CSL Limited is one of the world's largest biotechnology companies by market capitalisation, built on more than a century of plasma science and vaccine development. Founded in 1916 as the Commonwealth Serum Laboratories in Melbourne, Australia, the company has grown from a government research body into a global ASX- and ADR-listed biotherapeutics group operating across more than 100 countries. Plasma-Derived Therapies and Behring The company's flagship division, CSL Behring, is among the world's leading manufacturers of plasma-derived therapies , supplying immunoglobulins, albumin, coagulation factors, and specialty products to patients with rare and serious conditions including primary immune deficiencies, haemophilia, and hereditary angioedema. CSL Behring operates one of the largest plasma collection networks globally, with hundreds of donation centres across North America and Europe, underpinning a manufacturing supply chain that processes tens of millions of litres of plasma each year. Seqirus and Influenza Vaccine Leadership CSL's second major division, Seqirus, is one of the two largest influenza vaccine producers in the world. Operating high-containment manufacturing facilities in the United Kingdom, the United States, and Australia, Seqirus supplies seasonal and pandemic influenza vaccines to governments and healthcare systems globally, including longstanding contracts with national immunisation programmes. The division's cell-based and adjuvanted vaccine technologies are recognised by public health authorities as meaningful advances over traditional egg-based manufacturing. In 2022 CSL completed the acquisition of Vifor Pharma, a Swiss-headquartered specialist in iron deficiency , nephrology, and cardio-renal therapies, substantially expanding the group's product portfolio and its presence in hospital and renal care markets. CSL is headquartered in Melbourne, Australia, with major operational hubs in King of Prussia (Pennsylvania), Marburg (Germany), and Bern (Switzerland). The group invests heavily in research and development, with a pipeline spanning recombinant therapies, gene therapy, and next-generation plasma fractionation. CSL's scale, century-long heritage in biologics manufacturing, and vertically integrated plasma network position it as a critical supplier to healthcare systems managing rare, chronic, and infectious disease. Further information is available at csl.com.

The go-to daily news source for the global biopharma industry, Endpoints News covers clinical trials, drug approvals, regulatory decisions, and the business of drug development with a focus that competing outlets rarely match. Founded in 2016 by veteran journalist John Carroll, the publication built its reputation on breaking news and deeply reported stories aimed squarely at the professionals who run, fund, and work inside pharmaceutical and biotechnology companies. Endpoints reaches a subscriber base of researchers, executives, investors, and regulatory professionals who rely on its coverage to track pipeline developments , FDA and EMA actions, licensing deals, and IPO activity. Its morning newsletter, Endpoints Weekly, and real-time alerts have become standard reading across the industry, distinguishing Endpoints from broader business media through its specialist depth and speed. The outlet provides coverage across a wide range of therapy areas including oncology, rare disease, gene therapy, immunology, and neuroscience, following assets from early-stage research through approval and commercialisation. In 2022, Endpoints News was acquired by Citeline, a data and intelligence business serving the life sciences sector, which positioned the publication within a broader ecosystem of clinical and commercial intelligence tools. Based in Boston, Massachusetts, Endpoints operates as a specialist industry media brand with a global editorial remit, covering developments in the United States, Europe, and Asia. Its journalists attend major industry conferences and produce long-form investigative pieces alongside its rapid-fire news output. Further information is available at endpts.com.